2 Schemes for Multi-drug Resistant Pulmonary Tuberculosis:Cost-Effectiveness Analysis
- VernacularTitle:2种方案治疗耐多药肺结核的成本-效果分析
- Author:
Zhilian CHEN
- Publication Type:Journal Article
- Keywords:
Multi-drug resistant pulmonary tuberculosis;
Sparfloxacin;
Ofloxacin;
Cost-effectiveness analysis
- From:
China Pharmacy
2001;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the cost-effectiveness of two therapeutic schemes for treatment of multi-drug resistant pulmonary tuberculosis.METHODS:80 multi-drug resistant pulmonary tuberculosis patients were randomly assigned to receive Sparfloxacine(trial group)or Ofloxacin(control group)plus anti-TB drugs(Rifapentine,Pyrazinamide,Sodium Aminosalicylate.Protionamide and Ethambatol)for 12 months.The curative effects and adverse drug reactions were monitored and the cost-effectiveness analyses were conducted.RESULTS:The costs in two groups(Sparfloxacin vs.Ofloxacin)were 10 143.25 and 7 841.65yuan,respectively;the negative-conversion rates of sputum bacteria after treatment for 12 months were 90.0% and 70.0%,respectively(P
